Calvin Sandra's Form 4 filing
Travere Therapeutics, Inc. (TVTX) · filed Feb 2, 2023
- Accession no.
- 0001209191-23-006413
- Filed
- Feb 2, 2023
- Trade date
- Jan 31-Feb 2, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $44.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Calvin SandraCIK 0001882909 | Officer (SVP, Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 | Common Stock | AGrant or awardAcquired | +10,000 | $0.00 | $0 | 44,836 | Direct | |
| Feb 1, 2023 | Common Stock | SSaleDisposed | −1,671 | $21.75 | −$36,344.25 | 43,165 | Direct | |
| Feb 2, 2023 | Common Stock | SSaleDisposed | −360 | $22.42 | −$8,071.2 | 42,805 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2023 | Common Stock | AGrant or awardAcquired | +20,000 | $0.00 | $0 | 20,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.